Well I could not find the cost of care in a nursing home for a PDP patient so I will just use the Alzheimer's cost which is probably close.
" According to the MetLife Mature Market Study, 68% of assisted living communities surveyed nationwide provide dementia and Alzheimer’s care for their residents. The study also found that the national average for Alzheimer’s care costs at an assisted living community is $4,762 per month or $57,144 annually."
I don't know if this just covers the stay and not meds or other special therapy etc.
So PIMA can keep patients out of a SNF( Skilled Nursing Facility also call a "sniff " ) . Actually the Range I noted was $4+-7,000/month for Alzheimer's care in a SNF. So if PIMA cost say $10 /day = x 30 d = $300/mo that is still a great savings. You can calculate the cost per year if you knew exactly how many patients were treated. eg, 1 million PD patients in the USA alone...40% or 400,000 will get PDP at some point, if you consider say 100,000 pt's need treatment now....100K x $300/mon x 12= $360 Million per year in the USA only. So the real incentive is to keep PDP pt's out of the SNF. $300 per month is way better than $4-7,000 per month. The insurance companies will have tremendous pressure to cover the cost of PIMA since it will be the only drug indicated for PDP Even if they use protocols they will still be liable if the patients get the risky side effects to the of say Clozapine -
"Main side effects
Agranulocytosis (1%), seizures, myocarditis, gastrointestinal hypomotility, weight gain, diabetes mellitus or hyperglycemia, hypercholesterolemia, orthostatic hypotension, sedation, sialorrhea. Clozapine bears a “black box” warning of potential for increased mortality risk in elderly dementia patients on conventional or atypical antipsychotics. (Most deaths are due to cardiovascular or infectious events it remains unclear if the deaths are due to antipsychotics or to patient characteristics or the patient population.)"
$300 a month is way too low. It's going to get priced much higher than that. Just look at the cost of all the new drugs that don't have many treatment options. It will be interesting to see how the company prices it though.